BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Levadex: PD trial data

A double-blind, placebo-controlled, crossover, U.S. pharmacodynamic trial in 24 healthy volunteers showed no significant difference between orally inhaled Levadex and placebo on the primary endpoint of pulmonary artery pressure over 2 hours post treatment. Map also said that pulmonary artery pressure was higher in the IV DHE group vs. Levadex and vs....

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >